Yang et al., 2003 - Google Patents
MicroPET imaging of prostate cancer in LNCAP‐SR39TK‐GFP mouse xenograftsYang et al., 2003
- Document ID
- 7003789061954067718
- Author
- Yang H
- Berger F
- Tran C
- Gambhir S
- Sawyers C
- Publication year
- Publication venue
- The Prostate
External Links
Snippet
BACKGROUND The aim of this study was to develop models that allow serial, noninvasive imaging of human prostate cancer cells in immunodeficient mice using a dedicated small animal positron emission tomography scanner (microPET). METHODS LNCaP tumor cells …
- 238000003384 imaging method 0 title abstract description 40
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hildebrandt et al. | Molecular imaging applications for immunology | |
| Massoud et al. | Molecular imaging in living subjects: seeing fundamental biological processes in a new light | |
| Chatziioannou | PET scanners dedicated to molecular imaging of small animal models | |
| Deroose et al. | Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging | |
| MacLaren et al. | PET imaging of transgene expression | |
| Pomper et al. | Small animal imaging in drug development | |
| Yang et al. | MicroPET imaging of prostate cancer in LNCAP‐SR39TK‐GFP mouse xenografts | |
| Garai et al. | Limitations and pitfalls of 99mTc-EDDA/HYNIC-TOC (Tektrotyd) scintigraphy | |
| Castellucci et al. | PET/CT in prostate cancer: non-choline radiopharmaceuticals | |
| CN119330937B (en) | A probe precursor targeting CXCR4 receptor, a probe and its preparation method and application | |
| Hu et al. | Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint | |
| Handula et al. | Towards complete tumor resection: Novel dual-modality probes for improved image-guided surgery of grpr-expressing prostate cancer | |
| Kertész et al. | In vivo imaging of experimental melanoma tumors using the novel radiotracer 68Ga-NODAGA-procainamide (PCA) | |
| Nicolas et al. | Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: evaluation of sensitivity in a prospective phase II imaging study | |
| CN119930631B (en) | DDR1 receptor targeting compound and radioactive tracer derived from same | |
| Van Den Anker‐Lugtenburg et al. | Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease | |
| Schelbert et al. | PET imaging in small animals | |
| EP1418808B1 (en) | Imaging marker transgenes | |
| CN104447955B (en) | A kind of polypeptide combined with PSMA film outskirt targetings and its application | |
| Li et al. | 111In-DOTA-dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study | |
| Handula et al. | Towards complete tumor resection: novel dual-modality probes for improved image-guided surgery of GRPR-expressing prostate. Cancer Pharm. 2022b; 14 (1): 195–213 | |
| Biswal | Molecular imaging of musculoskeletal diseases | |
| Zhang et al. | RSC Chemical Biology | |
| CN117700485B (en) | Compound capable of simultaneously targeting PSMA and FAP as well as preparation method and application thereof | |
| EP2106804A2 (en) | Composition and method for detection of pre-metastatic sites |